|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Rana M, Kanatas A, Herzberg PY, Khoschdell
M, Kokemueller H, Gellrich NC and Rana M: Prospective study of the
influence of psychological and medical factors on quality of life
and severity of symptoms among patients with oral squamous cell
carcinoma. Br J Oral Maxillofac Surg. 53:364–370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kademani D: Oral cancer. Mayo Clin Proc.
82:878–887. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chi AC, Day TA and Neville BW: Oral cavity
and oropharyngeal squamous cell carcinoma - an update. CA Cancer J
Clin. 65:401–421. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shiboski CH, Schmidt BL and Jordan RCK:
Tongue and tonsil carcinoma: Increasing trends in the U.S.
population ages 20–44 years. Cancer. 103:1843–1849. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Choi SW, Moon EK, Park JY, Jung KW, Oh CM,
Kong HJ and Won YJ: Trends in the incidence of and survival rates
for oral cavity cancer in the Korean population. Oral Dis.
20:773–779. 2014.PubMed/NCBI
|
|
7
|
Patel SC, Carpenter WR, Tyree S, Couch ME,
Weissler M, Hackman T, Hayes DN, Shores C and Chera BS: Increasing
incidence of oral tongue squamous cell carcinoma in young white
women, age 18 to 44 years. J Clin Oncol. 29:1488–1494. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chinn SB and Myers JN: Oral Cavity
Carcinoma: Current Management, Controversies, and Future
Directions. J Clin Oncol. 33:3269–3276. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ebrahimi A, Zhang WJ, Gao K and Clark JR:
Nodal yield and survival in oral squamous cancer: Defining the
standard of care. Cancer. 117:2917–2925. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gellrich NC, Schimming R, Schramm A,
Schmalohr D, Bremerich A and Kugler J: Pain, function, and
psychologic outcome before, during, and after intraoral tumor
resection. J Oral Maxillofac Surg. 60:772–777. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
O-charoenrat P, Pillai G, Patel S, Fisher
C, Archer D, Eccles S and Rhys-Evans P: Tumour thickness predicts
cervical nodal metastases and survival in early oral tongue cancer.
Oral Oncol. 39:386–390. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Angadi PV, Patil PV, Hallikeri K, Mallapur
MD, Hallikerimath S and Kale AD: Tumor budding is an independent
prognostic factor for prediction of lymph node metastasis in oral
squamous cell carcinoma. Int J Surg Pathol. 23:102–110. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Srinivas PR, Verma M, Zhao Y and
Srivastava S: Proteomics for cancer biomarker discovery. Clin Chem.
48:1160–1169. 2002.PubMed/NCBI
|
|
14
|
Dabbous MK, Jefferson MM, Haney L and
Thomas EL: Biomarkers of metastatic potential in cultured
adenocarcinoma clones. Clin Exp Metastasis. 28:101–111. 2011.
View Article : Google Scholar
|
|
15
|
Poli G, Ceni E, Armignacco R, Ercolino T,
Canu L, Baroni G, Nesi G, Galli A, Mannelli M and Luconi M: 2D-DIGE
proteomic analysis identifies new potential therapeutic targets for
adrenocortical carcinoma. Oncotarget. 6:5695–5706. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Merkley MA, Weinberger PM, Jackson LL,
Podolsky RH, Lee JR and Dynan WS: 2D-DIGE proteomic
characterization of head and neck squamous cell carcinoma.
Otolaryngol Head Neck Surg. 141:626–632. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bijian K, Mlynarek AM, Balys RL, Jie S, Xu
Y, Hier MP, Black MJ, Di Falco MR, LaBoissiere S and Alaoui-Jamali
MA: Serum proteomic approach for the identification of serum
biomarkers contributed by oral squamous cell carcinoma and host
tissue microenvironment. J Proteome Res. 8:2173–2185. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cohen A, Wang E, Chisholm KA, Kostyleva R,
O’Connor-McCourt M and Pinto DM: A mass spectrometry-based plasma
protein panel targeting the tumor microenvironment in patients with
breast cancer. J Proteomics. 81:135–147. 2013. View Article : Google Scholar
|
|
19
|
Bayraktar E, Igci M, Erturhan S, Igci YZ,
Karakok M, Gogebakan B, Ulasli M, Cakmak EA and Arslan A: Reduced
gene expression of bikunin as a prognostic marker for renal cell
carcinoma. Exp Oncol. 36:107–111. 2014.PubMed/NCBI
|
|
20
|
Kobayashi H, Suzuki M, Kanayama N, Nishida
T, Takigawa M and Terao T: Suppression of urokinase receptor
expression by bikunin is associated with inhibition of upstream
targets of extracellular signal-regulated kinase-dependent cascade.
Eur J Biochem. 269:3945–3957. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Suzuki M, Kobayashi H, Tanaka Y, Hirashima
Y, Kanayama N, Takei Y, Saga Y, Suzuki M, Itoh H and Terao T:
Suppression of invasion and peritoneal carcinomatosis of ovarian
cancer cell line by overexpression of bikunin. Int J Cancer.
104:289–302. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koike H, Uzawa K, Nakashima D, Shimada K,
Kato Y, Higo M, Kouzu Y, Endo Y, Kasamatsu A and Tanzawa H:
Identification of differentially expressed proteins in oral
squamous cell carcinoma using a global proteomic approach. Int J
Oncol. 27:59–67. 2005.PubMed/NCBI
|
|
23
|
Onda T, Uzawa K, Nakashima D, Saito K,
Iwadate Y, Seki N, Shibahara T and Tanzawa H: Lin-7C/VELI3/MALS-3:
An essential component in metastasis of human squamous cell
carcinoma. Cancer Res. 67:9643–9648. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nishikawa H, Ooka S, Sato K, Arima K,
Okamoto J, Klevit RE, Fukuda M and Ohta T: Mass spectrometric and
mutational analyses reveal Lys-6-linked polyubiquitin chains
catalyzed by BRCA1-BARD1 ubiquitin ligase. J Biol Chem.
279:3916–3924. 2004. View Article : Google Scholar
|
|
25
|
Dyrlund TF, Poulsen ET, Scavenius C,
Sanggaard KW and Enghild JJ: MS Data Miner: A web-based software
tool to analyze, compare, and share mass spectrometry protein
identifications. Proteomics. 12:2792–2796. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hao P, Ren Y, Tam JP and Sze SK:
Correction of errors in tandem mass spectrum extraction enhances
phosphopeptide identification. J Proteome Res. 12:5548–5557. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sakuntabhai A, Ruiz-Perez V, Carter S,
Jacobsen N, Burge S, Monk S, Smith M, Munro CS, O’Donovan M,
Craddock N, et al: Mutations in ATP2A2, encoding a Ca2+
pump, cause Darier disease. Nat Genet. 21:271–277. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ruiz-Perez VL, Carter SA, Healy E, Todd C,
Rees JL, Steijlen PM, Carmichael AJ, Lewis HM, Hohl D, Itin P, et
al: ATP2A2 mutations in Darier’s disease: Variant cutaneous
phenotypes are associated with missense mutations, but
neuropsychiatric features are independent of mutation class. Hum
Mol Genet. 8:1621–1630. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ogane S, Onda T, Takano N, Yajima T,
Uchiyama T and Shibahara T: Spleen tyrosine kinase as a novel
candidate tumor suppressor gene for human oral squamous cell
carcinoma. Int J Cancer. 124:2651–2657. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
31
|
Lydiatt WM, Patel SG, O’sullivan B,
Brandwein MS, Ridge JA, Migliacci JC, Loomis AM and Shah JP: Head
and Neck cancers-major changes in the American Joint Committee on
Cancer eighth edition cancer staging manual. CA Cancer J Clin.
67:122–137. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hamm A, Veeck J, Bektas N, Wild PJ,
Hartmann A, Heindrichs U, Kristiansen G, Werbowetski-Ogilvie T, Del
Maestro R, Knuechel R, et al: Frequent expression loss of
Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple
human solid tumors: A systematic expression analysis. BMC Cancer.
8:25–40. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar
|
|
34
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bonner JA, Harari PM, Giralt J, Cohen RB,
Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, et al:
Radiotherapy plus cetuximab for locoregionally advanced head and
neck cancer: 5-year survival data from a phase 3 randomised trial,
and relation between cetuximab-induced rash and survival. Lancet
Oncol. 11:21–28. 2010. View Article : Google Scholar
|
|
37
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer H-R,
Cupissol D, et al: Platinum-based chemotherapy plus cetuximab in
head and neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for Recurrent Squamous-Cell Carcinoma of
the Head and Neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Akerström B, Lögdberg L, Berggård T,
Osmark P and Lindqvist A: α(1)-Microglobulin: A yellow-brown
lipocalin. Biochim Biophys Acta. 1482:172–184. 2000. View Article : Google Scholar
|
|
40
|
Fries E and Blom AM: Bikunin - not just a
plasma proteinase inhibitor. Int J Biochem Cell Biol. 32:125–137.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tanaka Y, Kobayashi H, Suzuki M, Kanayama
N, Suzuki M, Yamakawa T, Morishita H and Terao T: Reduced bikunin
gene expression as a factor of poor prognosis in ovarian carcinoma.
Cancer. 98:424–430. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pentenero M, Gandolfo S and Carrozzo M:
Importance of tumor thickness and depth of invasion in nodal
involvement and prognosis of oral squamous cell carcinoma: A review
of the literature. Head Neck. 27:1080–1091. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
D’Cruz AK, Vaish R, Kapre N, Dandekar M,
Gupta S, Hawaldar R, Agarwal JP, Pantvaidya G, Chaukar D, Deshmukh
A, et al Head and Neck Disease Management Group: Elective versus
therapeutic neck dissection in node-negative oral cancer. N Engl J
Med. 373:521–529. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dirven R, Ebrahimi A, Moeckelmann N, Palme
CE, Gupta R and Clark J: Tumor thickness versus depth of invasion -
Analysis of the 8th edition American Joint Committee on Cancer
Staging for oral cancer. Oral Oncol. 74:30–33. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Smith HW and Marshall CJ: Regulation of
cell signalling by uPAR. Nat Rev Mol Cell Biol. 11:23–36. 2010.
View Article : Google Scholar
|
|
46
|
Junttila MR, Li SP and Westermarck J:
Phosphatase-mediated crosstalk between MAPK signaling pathways in
the regulation of cell survival. FASEB J. 22:954–965. 2008.
View Article : Google Scholar
|
|
47
|
Shi Z and Stack MS: Urinary-type
plasminogen activator (uPA) and its receptor (uPAR) in squamous
cell carcinoma of the oral cavity. Biochem J. 407:153–159. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Montuori N, Pesapane A, Rossi FW, Giudice
V, De Paulis A, Selleri C and Ragno P: Urokinase type plasminogen
activator receptor (uPAR) as a new therapeutic target in cancer.
Transl Med UniSa. 15:15–21. 2016.PubMed/NCBI
|
|
49
|
Nishiwaki T, Daigo Y, Kawasoe T and
Nakamura Y: Isolation and mutational analysis of a novel human
cDNA, DEC1 (deleted in esophageal cancer 1), derived from the tumor
suppressor locus in 9q32. Genes Chromosomes Cancer. 27:169–176.
2000. View Article : Google Scholar
|
|
50
|
Ah-See KW, Cooke TG, Pickford IR, Soutar D
and Balmain A: An allelotype of squamous carcinoma of the head and
neck using microsatellite markers. Cancer Res. 54:1617–1621.
1994.PubMed/NCBI
|
